Cautious Hold Rating on Zura Bio Due to Efficacy Concerns and Competitive Risks

TipRanksDec 24 19:15 · Ratings

HC Wainwright & Co. Reiterates Neutral on Zura Bio, Maintains $5 Price Target

BenzingaDec 24 19:13 · Ratings

Express News | Zura Bio Launches Global Phase 2 Tibusure Study to Evaluate Tibulizumab in Adults With Systemic Sclerosis

BreakingsDec 23 19:44

Zura Bio Launches Global Phase 2 TibuSURE Study to Evaluate Tibulizumab in Adults With Systemic Sclerosis

BusinesswireDec 23 19:30

Leerink Partners Maintains Zura Bio(ZURA.US) With Buy Rating, Maintains Target Price $12

Futu NewsDec 21 02:31 · Ratings

Zura Bio (ZURA) Receives a Buy From Piper Sandler

TipRanksDec 12 19:46 · Ratings